-67%

est. 2Y upside i

InsurTechSeries B

Comulate is the accounting automation platform decisively chosen by today's and tomorrow's top 100, powering turnkey transformation with end-to-end automation across direct bill, cash application, carrier payables, revenue integrity, and beyond.

Rank

#2355

Sector

Insurtech

Est. Liquidity

~3Y

Data Quality

Data: High

Comulate presents a high-growth opportunity (tripled revenue in 12 months to 8-figure ARR) within the expanding Insurtech market, driven by its AI-powered automation.

Last updated: March 10, 2026

Bull (15%)+300%

Comulate successfully navigates the lawsuit with Applied Systems, potentially leading to a favorable settlement or a ruling that allows them to continue their market expansion. Their AI-powered platform gains significant traction, capturing substantial market share from legacy systems and driving ARR to over $90M by 2028, justifying a valuation of approximately $890M at a premium multiple.

Base (45%)+50%

Comulate continues its strong growth trajectory, albeit at a moderated pace due to ongoing competitive pressures and the legal battle with Applied Systems. They maintain their existing customer base and acquire new clients outside the scope of the injunction, reaching approximately $40M in ARR by 2028 and achieving a valuation of around $335M, representing a modest return for equity holders.

Bear (40%)-70%

The preliminary injunction significantly hampers Comulate's ability to acquire new customers, and the ongoing litigation with Applied Systems drains resources and distracts from product development. Growth stalls, leading to a down round or an acquisition at a distressed valuation of approximately $67M, resulting in substantial losses for common stock holders due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

11%

Investors have invested $25M, representing 11.2% of the current $223M valuation, meaning they hold a moderate liquidation preference ahead of common shareholders.

Dilution Risk

moderate

As a Series B company, Comulate will likely require at least one or two more funding rounds before a liquidity event, leading to further dilution for current equity holders.

Secondary Liquidity

none

There are no indications of active secondary markets or tender offers for Comulate's shares at this stage, especially given the ongoing litigation.

Engineering — 6 roles

Customer Operations — 1 role

Operations — 1 role

Product — 1 role

Talent — 1 role

View all 10 open roles at Comulate →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Comulate's data — designed to show you've done your homework.

  • 1

    “Given the recent preliminary injunction in the lawsuit with Applied Systems, how is Comulate adapting its go-to-market strategy and product development roadmap to mitigate the impact on new customer acquisition?”

  • 2

    “Comulate has demonstrated impressive revenue growth, scaling to 8-figure ARR in a short period. What are the key drivers for sustaining this growth trajectory, especially as Applied Systems launches its competing product, Applied Recon?”

  • 3

    “With the Series B funding secured in early 2025, what is the company's anticipated timeline for a potential liquidity event, and how does the ongoing litigation factor into those plans for employee equity holders?”

Community

Valuation Sentiment

Our model estimates -67% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.